S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China

Puma Biotechnology - PBYI Stock Forecast, Price & News

$4.24
-0.18 (-4.07%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.22
$4.51
50-Day Range
$3.98
$5.08
52-Week Range
$1.60
$5.16
Volume
234,692 shs
Average Volume
302,040 shs
Market Capitalization
$193.51 million
P/E Ratio
19.27
Dividend Yield
N/A
Price Target
$8.00

Puma Biotechnology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
88.7% Upside
$8.00 Price Target
Short Interest
Healthy
2.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.66mentions of Puma Biotechnology in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$176,342 Sold Last Quarter
Proj. Earnings Growth
-57.89%
From $0.19 to $0.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

124th out of 1,054 stocks

Pharmaceutical Preparations Industry

49th out of 517 stocks


PBYI stock logo

About Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
PBYI.OQ - | Stock Price & Latest News | Reuters
Puma Biotechnology, Inc. (PBYI)
Why Shares of Puma Biotechnology Rose This Week
15 Best Affordable Stocks Under $30
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
Short Volatility Alert: Puma Biotechnology, Inc.
H.C. Wainwright Keeps Their Buy Rating on Puma Biotechnology (PBYI)
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Profit Outlook
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Company Calendar

Last Earnings
11/03/2022
Today
1/29/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PBYI
Employees
196
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+88.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-29,130,000.00
Pretax Margin
4.64%

Debt

Sales & Book Value

Annual Sales
$253.20 million
Book Value
($0.06) per share

Miscellaneous

Free Float
35,964,000
Market Cap
$193.51 million
Optionable
Optionable
Beta
0.92

Key Executives

  • Mr. Alan H. AuerbachMr. Alan H. Auerbach (Age 53)
    Founder, Chairman, Pres, CEO & Sec.
    Comp: $1.11M
  • Mr. Maximo F. NouguesMr. Maximo F. Nougues (Age 54)
    CFO & Principal Accounting Officer
    Comp: $627.85k
  • Dr. Alvin F. Wong Pharm.d.
    Chief Scientific Officer
  • Mr. Douglas Hunt B.Sc. (Age 58)
    FRAPS, Sr. VP of Regulatory Affairs, Medical Writing & Project Management
    Comp: $509.04k
  • Mr. Jeffrey Jerome Ludwig (Age 57)
    Chief Commercial Officer
    Comp: $735.01k
  • Mr. Mariann Ohanesian
    Sr. Director of Investor Relations













PBYI Stock - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings
or view top-rated stocks.

What is Puma Biotechnology's stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month target prices for Puma Biotechnology's stock. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 88.7% from the stock's current price.
View analysts price targets for PBYI
or view top-rated stocks among Wall Street analysts.

How have PBYI shares performed in 2023?

Puma Biotechnology's stock was trading at $4.23 on January 1st, 2023. Since then, PBYI stock has increased by 0.2% and is now trading at $4.24.
View the best growth stocks for 2023 here
.

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our PBYI earnings forecast
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) released its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.10. The biopharmaceutical company had revenue of $57.10 million for the quarter, compared to analyst estimates of $51.40 million. Puma Biotechnology had a trailing twelve-month return on equity of 84.14% and a net margin of 4.50%.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.84%) and Patriot Financial Group Insurance Agency LLC (0.06%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Michael Patrick Miller, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $4.24.

How much money does Puma Biotechnology make?

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $193.51 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29,130,000.00 in net income (profit) each year or $0.22 on an earnings per share basis.

How many employees does Puma Biotechnology have?

The company employs 196 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.

This page (NASDAQ:PBYI) was last updated on 1/29/2023 by MarketBeat.com Staff